Acute Decompensated Heart Failure

Cardiovascular
4
Pipeline Programs
7
Companies
9
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Reprieve Cardiovascular
4 programs
1
Reprieve SystemPhase 31 trial
Reprieve Decongestion Management SystemN/A1 trial
Reprieve Decongestion Management SystemN/A1 trial
Reprieve SystemN/A1 trial
Active Trials
NCT06362668CompletedEst. Oct 2024
NCT05174312CompletedEst. Jan 2025
NCT06272734RecruitingEst. Dec 2026
+1 more trials
Bristol Myers Squibb
1 program
1
BMS-986259Phase 21 trial
Active Trials
NCT04318093Completed25Est. Jul 2021
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Empagliflozin 25 mgPhase 21 trial
Active Trials
NCT04049045Completed60Est. Jun 2021
Trevena
TrevenaPA - Chesterbrook
1 program
1
TRV027 Dose #1Phase 21 trial
Active Trials
NCT01966601Completed620Est. Sep 2016
Rhythm Pharmaceuticals
1 program
AVIVO™ PiiX Patch Monitor SystemN/A1 trial
Active Trials
NCT01574144Completed70Est. Aug 2013
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
ECG PatchN/A1 trial
Active Trials
NCT06243029Active Not Recruiting67Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Reprieve CardiovascularReprieve System
Bristol Myers SquibbBMS-986259
Boehringer IngelheimEmpagliflozin 25 mg
TrevenaTRV027 Dose #1
Reprieve CardiovascularReprieve Decongestion Management System
Reprieve CardiovascularReprieve System
AstraZenecaECG Patch
Reprieve CardiovascularReprieve Decongestion Management System
Rhythm PharmaceuticalsAVIVO™ PiiX Patch Monitor System

Clinical Trials (9)

Total enrollment: 842 patients across 9 trials

NCT06898515Reprieve CardiovascularReprieve System

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Start: Jul 2025Est. completion: Dec 2027
Phase 3Recruiting
NCT04318093Bristol Myers SquibbBMS-986259

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Start: Nov 2020Est. completion: Jul 202125 patients
Phase 2Completed
NCT04049045Boehringer IngelheimEmpagliflozin 25 mg

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Start: Sep 2019Est. completion: Jun 202160 patients
Phase 2Completed
NCT01966601TrevenaTRV027 Dose #1

A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

Start: Dec 2013Est. completion: Sep 2016620 patients
Phase 2Completed
NCT06362668Reprieve CardiovascularReprieve Decongestion Management System

EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)

Start: May 2024Est. completion: Oct 2024
N/ACompleted
NCT06272734Reprieve CardiovascularReprieve System

Reprieve System Pilot Study

Start: Jan 2024Est. completion: Dec 2026
N/ARecruiting
NCT06243029AstraZenecaECG Patch

A Study to Assess Multidomain Endpoints of an ECG Patch

Start: Jan 2024Est. completion: Feb 202667 patients
N/AActive Not Recruiting
NCT05174312Reprieve CardiovascularReprieve Decongestion Management System

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

Start: Jul 2022Est. completion: Jan 2025
N/ACompleted
NCT01574144Rhythm PharmaceuticalsAVIVO™ PiiX Patch Monitor System

REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)

Start: Apr 2012Est. completion: Aug 201370 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Associate Regulatory Affairs Specialist

Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr

Business Development Manager, Post Transplant, Cardio Thoracic

Thermo Fisher Scientific
Remote
Yesterday

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 842 patients
7 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)